Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102505 · ClinicalTrials.gov registry record · Phase 1
A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)
A Phase 1 study of Non-Small-Cell Lung Carcinoma and Carcinoma, Bronchogenic, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00102505 is a Phase 1 study of Non-Small-Cell Lung Carcinoma and Carcinoma, Bronchogenic that has completed, run by Pharmacyclics. The registered enrollment target is 36 participants, below the 235-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00102505, a Phase 1 study of Non-Small-Cell Lung Carcinoma and Carcinoma, Bronchogenic, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the dose limiting toxicities and maximum tolerated dose of motexafin gadolinium when administered with docetaxel and cisplatin in patients with Non-small Cell Lung Cancer. A cycle consists of 3 weeks. During week 1, patients receive MGd, docetaxel, and cisplatin treatment followed by 2 weeks without treatment. Eligible patients will receive 1 or 2 doses of MGd, depending on cohort, and a single dose of docetaxel and cisplatin at 75 mg/m² during the first week of each cycle. Additionally, tumor response will be evaluated at the end of even numbered cycles (2, 4, and 6). Patients may stay on the study a maximum of 6 cycles.
Conditions Studied
Interventions
- DRUG Motexafin Gadolinium Injection
Study Locations (1)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2004-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00102505
The ClinicalTrials.gov registry entry for NCT00102505 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 235-participant average among 30 other Non-Small-Cell Lung Carcinoma trials with a reported enrollment target (85% lower). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small-Cell Lung Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Motexafin Gadolinium Injection is the first listed.
NCT00102505 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT00102505 about?
NCT00102505 is a clinical study titled "A Study of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC)". The purpose of the study is to determine the dose limiting toxicities and maximum tolerated dose of motexafin gadolinium when administered with docetaxel and cisplatin in patients with Non-small Cell Lung Cancer. A cycle consists of 3 weeks. During week 1, patients receive MGd, docetaxel, and cispl...
What is the current status of trial NCT00102505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2004-11.
What conditions does trial NCT00102505 study?
This clinical trial studies the following conditions: Non-Small-Cell Lung Carcinoma, Carcinoma, Bronchogenic.
What interventions are being tested in trial NCT00102505?
The interventions under investigation include: Motexafin Gadolinium Injection (DRUG).
Who is sponsoring clinical trial NCT00102505?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00102505 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small-Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC
RECRUITING · Phase 1
-
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Retifanlimab and Ruxolitinib In Solid Malignancies
RECRUITING · Phase 1
-
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
RECRUITING · Phase 1
-
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
ACTIVE NOT RECRUITING · Phase 1
-
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.